Top 5 Target	Count

VISTA(V-domain Ig suppressor of T-cell activation)	2
CD28 x VISTA	2
VSIG4(V-set and immunoglobulin domain-containing protein 4)	1
PD-1(Programmed cell death protein 1)	1
CD39(Ectonucleoside triphosphate diphosphohydrolase 1)	1

Drugs associated with Sensei Biotherapeutics, Inc.

Cemiplimab-RWLC

Target

PD-1

Mechanism

PD-1 inhibitors

Active Org.

Regeneron Pharmaceuticals, Inc. [+16]

Originator Org.

Regeneron Pharmaceuticals, Inc.

Active Indication

Metastatic Carcinoma to the Uterine Cervix [+86]

Inactive Indication

Advanced Bile Duct Carcinoma [+18]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date28 Sep 2018

Solnerstotug

Target

VISTA

Mechanism

VISTA inhibitors

Active Org.

Sensei Biotherapeutics, Inc.

Originator Org.

Sensei Biotherapeutics, Inc.

Active Indication

Advanced cancer [+18]

Inactive Indication-

Drug Highest PhasePhase 1/2

First Approval Ctry. / Loc.-

First Approval Date-

PH Selective Anti-CD28/VISTA Bispecific Antibody

Target

CD28 x VISTA

Mechanism

CD28 agonists [+1]

Active Org.

Sensei Biotherapeutics, Inc.

Originator Org.

Sensei Biotherapeutics, Inc.

Active Indication

Neoplasms

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Sensei Biotherapeutics, Inc.

NCT05864144

/ RecruitingPhase 1/2

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.

Start Date31 May 2023

Sponsor / Collaborator

Sensei Biotherapeutics, Inc.

[+1]

NCT04217720

/ WithdrawnPhase 2

An Open-Label, Multi-Center Phase 2 Clinical Trial Evaluating SNS-301 in Patients With ASPH+ High Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 in patients with ASPH+ high risk MDS and CMML.

Start Date01 Apr 2020

Sponsor / Collaborator

Sensei Biotherapeutics, Inc.

NCT04034225

/ TerminatedPhase 1/2

An Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck

To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 added to checkpoint inhibitor therapy in locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN) patients.

Start Date11 Nov 2019

Sponsor / Collaborator

Sensei Biotherapeutics, Inc.

100 Clinical Results associated with Sensei Biotherapeutics, Inc.

0 Patents (Medical) associated with Sensei Biotherapeutics, Inc.

Literatures (Medical) associated with Sensei Biotherapeutics, Inc.

01 Dec 2023·JAMA oncology

Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma

Article

Author: Riddell, Stanley R ; Loggers, Elizabeth T ; Yu, Yuexin ; Schroeder, Brett A ; Ter Meulen, Jan ; Alexiev, Borislav A ; Wagner, Michael J ; Hsu, Cynthia ; Berglund, Peter ; Kane, Gabrielle ; O'Malley, Ryan B ; Cranmer, Lee D ; Jones, Robin L ; Smythe, Kimberly ; Black, Graeme ; Seo, Yongwoo David ; Bonham, Lynn ; Pierce, Robert H ; Kim, Edward Y ; Pillarisetty, Venu G ; Hsu, Frank J ; Pollack, Seth M ; Mi, Xinlei ; Warren, E Houston ; Lu, Hailing ; Hermida de Viveiros, Pedro ; Ng, Juliana

Importance:

Metastatic soft tissue sarcomas (STSs) have limited systemic therapy options, and immunomodulation has not yet meaningfully improved outcomes. Intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist glycopyranosyl lipid A in stable-emulsion formulation (GLA-SE) has been studied as immunotherapy in other contexts.

Objective:

To evaluate the safety, efficacy, and immunomodulatory effects of IT GLA-SE with concurrent radiotherapy in patients with metastatic STS with injectable lesions.

Design, Setting, and Participants:

This phase 1 nonrandomized controlled trial of patients with STS was performed at a single academic sarcoma specialty center from November 17, 2014, to March 16, 2016. Data analysis was performed from August 2016 to September 2022.

Interventions:

Two doses of IT GLA-SE (5 μg and 10 μg for 8 weekly doses) were tested for safety in combination with concurrent radiotherapy of the injected lesion.

Main Outcomes and Measures:

Primary end points were safety and tolerability. Secondary and exploratory end points included local response rates as well as measurement of antitumor immunity with immunohistochemistry and T-cell receptor (TCR) sequencing of tumor-infiltrating and circulating lymphocytes.

Results:

Twelve patients (median [range] age, 65 [34-78] years; 8 [67%] female) were treated across the 2 dose cohorts. Intratumoral GLA-SE was well tolerated, with only 1 patient (8%) experiencing a grade 2 adverse event. All patients achieved local control of the injected lesion after 8 doses, with 1 patient having complete regression (mean regression, −25%; range, −100% to 4%). In patients with durable local response, there were detectable increases in tumor-infiltrating lymphocytes. In 1 patient (target lesion −39% at 259 days of follow-up), TCR sequencing revealed expansion of preexisting and de novo clonotypes, with convergence of numerous rearrangements coding for the same binding sequence (suggestive of clonal convergence to antitumor targets). Single-cell sequencing identified these same expanded TCR clones in peripheral blood after treatment; these T cells had markedly enhanced Tbet expression, suggesting TH1 phenotype.

Conclusions and Relevance:

In this nonrandomized controlled trial, IT GLA-SE with concurrent radiotherapy was well tolerated and provided more durable local control than radiotherapy alone. Patients with durable local response demonstrated enhanced IT T-cell clonal expansion, with matched expansion of these clonotypes in the circulation. Additional studies evaluating synergism of IT GLA-SE and radiotherapy with systemic immune modulation are warranted.

Trial Registration:

ClinicalTrials.gov Identifier: NCT02180698

30 Aug 2023·Antibodies (Basel, Switzerland)

Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics.

Review

Author: Smith, F Donelson ; van der Horst, Edward H ; Pierce, Robert H ; Thisted, Thomas

Immune checkpoints and other immunoregulatory targets can be difficult to precisely target due to expression on non-tumor immune cells critical to maintaining immune homeostasis in healthy tissues. On-target/off-tumor binding of therapeutics results in significant pharmacokinetic and pharmacodynamic problems. Target-mediated drug disposition (TMDD) significantly limits effective intratumoral drug levels and adversely affects anti-tumor efficacy. Target engagement outside the tumor environment may lead to severe immune-related adverse events (irAEs), resulting in a narrowing of the therapeutic window, sub-optimal dosing, or cessation of drug development altogether. Overcoming these challenges has become tractable through recent advances in antibody engineering and screening approaches. Here, we review the discovery and development of conditionally active antibodies with minimal binding to target at physiologic pH but high-affinity target binding at the low pH of the tumor microenvironment by focusing on the discovery and improved properties of pH-dependent mAbs targeting two T cell checkpoints, VISTA and CTLA-4.

14 Apr 2022·Clinical cancer research : an official journal of the American Association for Cancer ResearchQ1 · MEDICINE

Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells

Q1 · MEDICINE

Article

Author: LaFleur, Bonnie J. ; Thompson, Matthew J. ; Pollack, Seth M. ; Zhang, Yuzheng ; Jones, Robin L. ; Riolobos, Laura ; McClanahan, Terrill K. ; LaFranzo, Natalie A. ; Loggers, Elizabeth T. ; Murphy, Erin ; Ricciotti, Robert ; Chen, Eleanor Y. ; Kim, Teresa S. ; Goff, Peter H. ; Blumenschein, Wendy M. ; Seo, Y. David ; Kim, Edward Y. ; Schaub, Stephanie K. ; Kane, Gabrielle M. ; Earls, Jon ; Spraker, Matthew B. ; Wagner, Michael J. ; Flanagan, Kevin C. ; Campbell, Jean S. ; Smythe, Kimberly S. ; He, Qianchuan ; Cranmer, Lee D. ; Mantilla, Jose G. ; Pierce, Robert H.

Abstract:

Purpose::

To characterize changes in the soft-tissue sarcoma (STS) tumor immune microenvironment induced by standard neoadjuvant therapy with the goal of informing neoadjuvant immunotherapy trial design.

Experimental Design::

Paired pre- and postneoadjuvant therapy specimens were retrospectively identified for 32 patients with STSs and analyzed by three modalities: multiplexed IHC, NanoString, and RNA sequencing with ImmunoPrism analysis.

Results::

All 32 patients, representing a variety of STS histologic subtypes, received neoadjuvant radiotherapy and 21 (66%) received chemotherapy prior to radiotherapy. The most prevalent immune cells in the tumor before neoadjuvant therapy were myeloid cells (45% of all immune cells) and B cells (37%), with T (13%) and natural killer (NK) cells (5%) also present. Neoadjuvant therapy significantly increased the total immune cells infiltrating the tumors across all histologic subtypes for patients receiving neoadjuvant radiotherapy with or without chemotherapy. An increase in the percentage of monocytes and macrophages, particularly M2 macrophages, B cells, and CD4+ T cells was observed postneoadjuvant therapy. Upregulation of genes and cytokines associated with antigen presentation was also observed, and a favorable pathologic response (≥90% necrosis postneoadjuvant therapy) was associated with an increase in monocytic infiltrate. Upregulation of the T-cell checkpoint TIM3 and downregulation of OX40 were observed posttreatment.

Conclusions::

Standard neoadjuvant therapy induces both immunostimulatory and immunosuppressive effects within a complex sarcoma microenvironment dominated by myeloid and B cells. This work informs ongoing efforts to incorporate immune checkpoint inhibitors and novel immunotherapies into the neoadjuvant setting for STSs.

News (Medical) associated with Sensei Biotherapeutics, Inc.

31 Jan 2025

·www.businesswire.com

CD39 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market Opportunity Insight 2025: First CD39 Targeted Therapy Approval Expected By 2029 - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "CD39 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market Opportunity Insight 2025" report has been added to ResearchAndMarkets.com's offering. CD39 targeting therapies are emerging as a promising strategy for modulating immune responses in a range of diseases. CD39 serves as a vital ectonucleotidase that influences the purinergic signaling pathway, thereby regulating the equilibrium between immune activation and suppression. By converting ATP into AMP, which is further transformed into adenosine by CD73, CD39 is instrumental in establishing an immunosuppressive microenvironment. This environment is particularly advantageous for tumors but also plays a role in chronic infections and autoimmune diseases. Inhibiting CD39 activity may restore immune functionality and enhance patient outcomes in these contexts. Report Highlights: First CD39 Targeted Therapy Approval Expected By 2029 CD39 Targeted Therapies In Clinical Trials: > 15 Therapies CD39 Inhibitors Clinical Trials Insight By Company, Country, Indication and Phase CD39 Targeted Therapy Research and Development Trends By Indication CD39 Targeted Therapies Proprietary Technologies Platforms By Company In the realm of oncology, the contribution of CD39 to immune suppression within the tumor microenvironment (TME) is well-established. Tumors frequently utilize the CD39-CD73-adenosine axis to evade immune surveillance, resulting in immune cell exhaustion and diminished anti-tumor responses. Elevated levels of CD39 on regulatory T cells (Tregs) and CD8+ T cells have been associated with unfavorable prognoses in various malignancies. By employing monoclonal antibodies that target CD39, such as IPH5201, it is possible to reactivate the immune system to more effectively combat tumor cells. IPH5201, which is being developed by Innate Pharma and AstraZeneca, is currently under investigation in conjunction with immune checkpoint inhibitors (ICIs) to enhance the immune response in patients with solid tumors. In addition to cancer, CD39-targeting therapies show considerable potential for addressing other diseases, particularly chronic viral infections, autoimmune disorders, and sepsis. In the context of chronic infections like HIV, tuberculosis, and Chagas disease, CD39 is implicated in immune exhaustion and suppression, which obstructs effective immune responses. By inhibiting CD39, there is a possibility of reversing immune dysfunction and improving the body's capacity to eliminate pathogens. In autoimmune disorders, where there is an overactivation of the immune system, the targeting of CD39 may aid in reestablishing equilibrium by enhancing the inhibitory function of regulatory T cells, which are vital for averting tissue damage. The therapeutic promise of targeting CD39 also encompasses sepsis, as CD39 expression on monocytes and macrophages is instrumental in regulating inflammation. In the context of sepsis, achieving a balanced immune response is crucial to mitigate tissue injury while effectively managing infection. By inhibiting the activity of CD39, therapeutic interventions could diminish excessive inflammation and restore immune homeostasis, presenting a novel strategy for addressing this critical condition. The clinical advancement of therapies aimed at CD39 is still in its nascent phase, with several candidates progressing through clinical trials, particularly in Phase 2. Among these, IPH5201 stands out as a leading candidate, demonstrating encouraging outcomes in both preclinical and early-phase clinical investigations. These antibodies are being assessed not only in oncology but also across a range of chronic conditions where CD39 plays a significant role in immune regulation. By focusing on CD39, these therapies seek to bolster immune responses in scenarios characterized by immune suppression or dysfunction. Looking forward, the potential uses of CD39-targeting therapies are extensive. The integration of anti-CD39 antibodies with other treatment modalities, such as immune checkpoint inhibitors or antiviral therapies, presents the opportunity for synergistic effects, thereby enhancing the immune response. Nonetheless, challenges persist, particularly concerning the context-dependent function of CD39 across various diseases and patient demographics. Achieving a precise balance between immune activation and suppression will be essential for the safe and effective implementation of these therapies. As clinical trials advance and additional data is collected, therapies targeting CD39 may emerge as a fundamental component of personalized medicine, effectively addressing various diseases through the precise and controlled modulation of immune responses. Key Topics Covered: Introduction To CD39 Targeting Therapies Role of CD39 & Emergence As Therapeutic Target Discovery of CD39 & Development Of Targeting Therapies CD39 Targeting Therapies Mechanism Of Action CD39 Inhibition CD39 Agonism Current CD39 Targeting Therapy Approaches Antibodies Nucleic Acid Therapeutics Small Molecule Inhibitors Global CD39 Targeted Therapies Clinical Trials Overview By Company By Indication By Country By Phase CD39 Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase Research Preclinical Phase I Phase II Global CD39 Targeting Therapy Market Trends & Developments Current Market Outline Future Market Opportunities Role Of CD39 Targeting Therapies By Indication: Clinical Development & Collaborations Cancer Autoimmune & Inflammatory Diseases Cardiovascular Diseases Infections CD39 Targeted Therapies Technology Platforms OligoCreator & LNAplus Platforms - Secarna Pharmaceuticals Unnamed Platforms - Biotheus Unnamed Platform - Adimab OriAb Antibody Discovery Platform - Oricell Therapeutics TMAb Platform - Sensei Biotherapeutics Global CD39 Targeted Therapies Market Dynamics Market Drivers & Opportunities Market Challenges & Restraints Competitive Landscape Adimab Arcus Biosciences Biotheus BrightPath Biotherapeutics Elpiscience Biopharmaceuticals Innate Pharma Orega Biotech OriCell Therapeutics Secarna Pharmaceuticals Trishula Therapeutics For more information about this report visit https://www.researchandmarkets.com/r/pftdih About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ImmunotherapyPhase 2Phase 1

03 Dec 2024

·www.echemi.com

Over 2,000 Layoffs in 19 Global Pharma Companies, Johnson & Johnson and Merck Restructure Operations in China

According to the latest monitoring data, at least 19 pharmaceutical companies globally announced layoffs or business streamlining plans in November. The impact on multinational pharmaceutical companies operating in China has been particularly significant, with Johnson & Johnson and Merck implementing layoffs in the country. Johnson & Johnson's layoffs in China reached 2,000 people, approximately 20% of its total workforce, mainly affecting the surgical division. The layoffs were primarily due to declining company performance, especially in its ultrasound knife business, which saw its market share plunge from 95% to less than 30%. Since the second quarter of this year, Johnson & Johnson has also undergone business adjustments, with several senior executives, including the president of China, Song Weiqun, leaving the company. Merck also conducted staff reductions in its China division, although the exact number of layoffs has not been specified, primarily affecting the diabetes department. Due to the impact of centralized procurement policies, Merck's diabetes drug business has suffered significantly, forcing the company to take measures to drastically reduce costs. In recent years, centralized procurement policies have driven down drug prices, leading to significant profit reductions for pharmaceutical companies, which have had to scale back or sell their operations in China in response. For example, Pfizer sold its PCV13 vaccine business and conducted extensive layoffs. In this context, other pharmaceutical companies have also announced restructuring plans. Sana Biotechnology is shifting its research focus from cancer to autoimmune diseases and has undergone strategic restructuring, though it has not disclosed the number of layoffs. Viracta Therapeutics, focusing on precision oncology, announced approximately 42% layoffs to concentrate resources on its Nana-val development project. Aurinia laid off 45% of its workforce due to an inability to find a buyer, aiming to maintain cash flow. A gene sequencing company announced a 40% reduction in staff and the termination of all therapeutic projects due to declining business and cash flow issues. Marinus Pharmaceuticals announced a 45% reduction in staff following the failure of its core drug in Phase III clinical trials. Adaptimmune stated it would lay off 33% of its workforce in Q1 2025, aiming to save $300 million over the next four years and achieve break-even by 2027. Additionally, companies such as Gilead, Sensei Biotherapeutics, Sonata, Lexicon Pharmaceuticals, Bristol-Myers Squibb, Alector, Medigene, Novartis, and Kronos Bio have also announced layoffs or restructuring plans to respond to the current challenges in the pharmaceutical industry. These measures reflect the strategies adopted by the pharmaceutical industry in the face of market changes and policy adjustments.

VaccinePhase 3Financial Statement

27 Nov 2024

·www.globenewswire.com

Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi’s 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL. About Sensei Biotherapeutics Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn. Investor Contact:Michael BiegaSenior Director, Investor RelationsSensei Biotherapeuticsmbiega@senseibio.com Media Contact:Joyce AllaireLifeSci AdvisorsJallaire@lifesciadvisors.com

Immunotherapy

100 Deals associated with Sensei Biotherapeutics, Inc.

100 Translational Medicine associated with Sensei Biotherapeutics, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 27 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Phase 2

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Cemiplimab-RWLC ( PD-1 )	Advanced Malignant Solid Neoplasm More	Phase 1/2
Solnerstotug ( VISTA )	Kidney Neoplasms More	Phase 1/2
SNS-103 ( CD39 )	Solid tumor More	Preclinical
PH Selective Anti-CD28/VISTA Bispecific Antibody ( CD28 x VISTA )	Neoplasms More	Preclinical
SNS-VSIG4 ( VSIG4 )	Solid tumor More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis